Document:

EXHIBIT
10.2

Regent Private Capital, LLC

December 23,
2009

Vycor Medical,
Inc.

80 Orville Drive, Suite 100

Bohemia, New York 11716

	
  

 	
  

 	
  

 
	
  

 	
 Re:

 	
 Waiver of
 (1) Anti-Dilution Rights with respect to Warrant dated December 15, 2006; (2)
 Default on Debentures and (3) Minority Rights Approval; and (4) No Action

 

Ladies and
Gentlemen:

The purpose of
this letter agreement is to confirm the following agreements by Regent Private
Capital, LLC (“Regent”) relative to the matters detailed below

Waiver of
Anti-Dilution Rights with respct to Warrant Dated December 15, 2006:

On December
15, 2006, Vycor Medical, LLC issued a Warrant (“Warrant”) to Fountainhead
Capital Partners Limited, to purchase 50.22 units Vycor Medical, LLC at an
exercise price of $7,965 per unit. Thereafter, Vycor was converted into a
Delaware corporation, Vycor Medical, Inc. (“Vycor”) and the Warrant thereafter
became exercisable as to 805,931 shares $.50 per share. Effective February 15,
2008, Fountainhead Capital Partners Limited assigned its interest in the
Warrant to Fountainhead Capital Management Limited (“FCM”) which assigned
one-half of its interest in the Warrant to Regent.

The Warrant
contained certain anti-dilution provisions in paragraph 6 thereof which
provided for adjustments of the conversion price upon the occurrence of certain
events. In a Term Sheet dated as of November 6, 2009, FCM and Regent agreed to
a series of transactions as a part of a restructuring of FCM’s and Regent’s
relationship with Vycor, including but not limited to an exchange of certain
Debentures (the “Restructuring”).

By this
letter, Regent confirms that it is waiving any and all of the anti-dilution
provisions of the Warrant as such may be applicable to the various transactions
comprising the Restructuring. Such waiver shall not be effective to any other
events detailed in such anti-dilution provisions other than those actions which
are specifically related to the Restructuring, and in particular does not
affect the price adjustment provisions in paragraph 11 of the Warrant.

Default on
Debentures:

Vycor is in
default on certain of its obligations related to certain Debentures issued by
Vycor to Regent. As a result of the Restructuring, Regent has agreed to
exchange all of the said 

Vycor Medical,
Inc.

December 23, 2009

Page 2

Debentures for
new Debentures with extended maturity dates and certain other defaults with
respect thereto have been cured. Regent hereby advises Vycor that as of the
closing of the Restructuring, and the exchange of the old Debentures for the
new Debentures, Vycor will not be in default of any provisions of said
Debentures. 

By this
letter, Regent confirms that it rescinds any notices of default previously
issued on account of said Debentures, including but not limited to any
forbearance proposals or agreements and waives its right to take any action
with respect to any default thereon which may have occurred prior to the date
of this letter. Nothing in this letter shall be deemed to waive any default by
Vycor which may occur after the date of this letter.

Minority Rights
Approval:

Pursuant to
section 6.2 of that certain Convertible Debenture Purchase Agreement dated as
of February 15, 2008 (“Debenture Purchase Agreement”), Regent was granted
certain minority approval rights with respect to the certain prospective
actions by Vycor described therein. 

By this
letter, Regent confirms that it forever waives each and every right granted it
pursuant to said section 6.2 of the Debenture Purchase Agreement and agrees and
acknowledges that said section 6.2 shall be of no further force and effect as
of the date hereof. 

In all other
respects, other than as specifically modified in connection with the
Restructuring, all other rights and remedies Regent may have with respect to
any aspect of its relationship with Vycor shall remain unchanged.

No Action:

The
undersigned agree and covenant that they will not initiate any legal action or
seek any other legal recourse against Vycor or Fountainhead Capital Partners
Limited on account of any matters which are the subject of this letter.

Sincerely,

	
  

 	
  

 	
  

 
	
 REGENT
 PRIVATE CAPITAL, LLC

 	
  

 
	
  

 	
  

 	
  

 
	
  

 	
 /s/ Lawrence Field

 	
  

 
	
 By: 

 	
 ______________________________

 	
  

 
	
  

 	
 Lawrence
 Field

 	
  

 
	
  

 	
 Managing
 DurectorEXHIBIT 10.3

EMPLOYMENT AGREEMENT

          AGREEMENT
(the “Agreement”) dated as of December 29, 2009, between VYCOR MEDICAL, INC., a Delaware corporation
(“Company”), and KENNETH T. COVIELLO, an individual (“Executive”).

          This
Agreement replaces and supersedes in all respects all prior employment
agreements and arrangements between the Company and the Executive, including
but not limited to that certain Employment Agreement between the parties dated
as of January 1, 2008.

          Company
desires to employ Executive, and Executive desires to be employed, as Chief
Executive Officer (“CEO”) of Company, in each case, on the terms and subject to
the conditions set forth in this Agreement.

          This
Agreement is entered into by the parties as part and parcel of a restructuring
arrangement (the “Restructuring”) by and between the Company and Fountainhead
Capital Management Limited (“Fountainhead”). This Agreement shall take effect
concurrent with the closing of the Restructuring and will be of no force and
effect unless and until the closing of the restructuring.

          Accordingly,
each party hereto hereby agrees as follows:

1. TERM OF AGREEMENT

          The
term of this Agreement will commence on the date first set forth above and will
continue until a date which is ninety (90) days thereafter (the “Initial
Term”). At the conclusion of the Initial Term, and each successive term
thereafter, this Agreement will be automatically renewed for an additional
thirty (30) day term, unless either party hereto gives written notice to the
other party of its intention to terminate this Agreement at least 30 days prior
to the automatic renewal date.

2. EMPLOYMENT

          2.1
Position
and Duties. Executive will serve as Company’s President, reporting
directly to Company’s Board of Directors (the “Board”), and will have the
general powers, duties and responsibilities of management usually vested in
that office in a corporation and such additional powers and duties as may be
prescribed from time to time by the Board, which may include services for one
or more subsidiaries or affiliates of Company. Executive’s responsibilities are
detailed in Exhibit A attached hereto and incorporated by reference, with the
understanding that such description is not intended to be exclusive, and will
receive performance appraisals on or about each anniversary of this Agreement
by the compensation committee of the Board. 

-1-

          2.2
Other
Services. Company acknowledges that Executive may do educational and
charity work and conduct personal business as long as such activities do not
interfere with Executive’s duties hereunder.

3. COMPENSATION

          3.1
Compensation.
During the term of this Agreement, Company will pay the amounts and provide the
benefits described in this Section 3, and Executive agrees to accept such
amounts and benefits in full payment for Executive’s services under this
Agreement.

          3.2
Base
Salary. Commencing the date of this Agreement, the Company will pay
to Executive a base salary of $8,500.00 per month, payable in bi-weekly
instalments in accordance with Company’s standard payroll practices, less
applicable withholding. On the earlier to occur of (i) the closing of a Company
fundraising of more than $1.5 million, or (ii) the Company’s achievement of
positive cash flow (based upon financial statements prepared in accordance with
US GAAP) for at least three consecutive months, the base salary shall increase
effective the beginning of the immediately succeeding fiscal quarter to the
equivalent of $165,000 per annum. Notwithstanding the foregoing, if the
Company’s cash flow calculated on the same basis for any of the succeeding
three months is negative, Executive agrees to discuss an adjustment of such
increased base salary until the Company again achieves positive cash flow for a
period of three consecutive months. In addition, any increase in salary shall
also be subject to the agreement of any new investors in the Company who make
their investment following the date of this Agreement. Other than the
foregoing, no increase in base salary shall be approved by the Company without
the expressed consent of Fountainhead Capital Management Limited.

          3.3
Cash
Bonus. In addition to Base Salary, Executive shall be paid an
incremental cash bonus, payable monthly in arrears, equivalent to 5% per month
of the Company’s gross profit (sales, less commission, less Cost of Goods Sold)
over $7,155 per month. Incremental sales must be on normal payment terms.

          3.4
Accrual of Past Salary. Executive
acknowledges that the Company has accrued past, but unpaid, salaries payable to
the Executive in the amount of $70,643 (the “Accrued Salary”). Executive waives
any claim to any amount of additional unpaid salary through the date of this
Agreement. The Accrued Salary is hereby converted into a contingent retention
bonus payable (assuming that the Executive continues to be in the employ of the
Company at the time) either on the closing of a Company fundraising of more
than $1.5 million or on the sale of the Company (or substantially all of its
assets) at a value above $3 million. Should the Executive be Terminated Without
Cause or Resign With Good Reason within a period of six months prior to either
of these two events occurring, the retention bonus will be payable

          3.5
Equity
Incentive Plan. Prior to March 31, 2010, the Company’s Board of
Directors, subject to the approval of Fountainhead, shall develop an incentive
plan for Management which will provide incentive compensation for Management
and key employees consistent with industry standards based on the achievement
of pre-determined financial milestones. 

-2-

          3.6
Fringe
Benefits. Company will provide to Executive health care insurance,
insurance and other employee benefits which have been provided by the Company
consistent with past practices and the Company’s Employee Manual 

          3.7
Automobile
Allowance. None.

          3.8
Paid
Vacation. Executive will accrue, on a daily basis, a total of three
workweeks of paid vacation (“Vacation”) per year following the date of this
Agreement. This Vacation will be in addition to normal Company holidays, which
will be determined at the discretion of Company from time to time. Any accrued
but unused Vacation (up to such limits as Company may establish) will be paid
to Executive, on a pro rata basis, at the time that his employment is
terminated. 

          3.9
Deductions
from Compensation. Company will deduct and withhold from all
compensation payable to Executive all amounts required to be deducted or
withheld pursuant to any present or future law, ordinance, regulation, order,
writ, judgment, or decree requiring such deduction and withholding.

4.
REIMBURSEMENT OF CERTAIN EXPENSES

          4.1
Travel
and Other Expenses. Company will pay to or reimburse Executive for
reasonable and necessary business, travel, promotional, professional continuing
education and licensing costs (to the extent required), professional society
membership fees, seminars and similar expenditures incurred by Executive for which
Executive submits appropriate receipts and indicates the amount, date, location
and business character in a timely manner.

          4.2
Liability
Insurance. Company will add Executive to the coverage of Company’s
officers and directors’ insurance and other liability insurance policies,
consistent with usual and reasonable business practices, to cover Executive
against insurable events related to his employment with Company.

          4.3
Indemnification.
The Company shall indemnify the Executive, and hold him harmless, to the
maximum extent permitted under law, if he is a party or is threatened to be
made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative, other
than an action by or in the right of the Company or its affiliates, by reason
of the fact that the Executive is or was a director, officer, employee or agent
of the Company or its affiliates, or is or was serving at the request of the
Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against all expenses,
including attorneys’ fees, judgments, fines and amounts paid in settlement.
Expenses incurred by the Executive in defending a civil or criminal action,
suit or proceeding referenced herein shall be promptly and timely paid by the
Company in advance of the final disposition of such action, suit or proceeding
at the written request of the Executive, provided the Executive agrees to repay
such amount to the extent that it is ultimately determined that the Executive
is not entitled to indemnification. The right to indemnification or advances as

-3-

provided by
this Agreement shall be enforceable by the Executive in any court of competent
jurisdiction. The Executive’s expenses incurred in connection with successfully
establishing the Executive’s right to indemnification or advances, in whole or
in part, in any civil or criminal action, suit or proceeding shall also be
indemnified by the Company. Notwithstanding any other provision of this
Agreement, the Company hereby agrees to indemnify the Executive to the full
extent permitted by law, notwithstanding that such indemnification is not
specifically authorized by the other provisions of this Agreement, the
Company’s Certificate of Incorporation, the Bylaws or by statute. In the event
of any changes, after the date of this Agreement, in any applicable law,
statute or rule which expand the right of a Delaware corporation to indemnify
an officer, supervisor or employee of the Company, such changes shall be within
the purview of the Executive’s rights, and the Company’s obligations, under
this Agreement. In the event of any changes in any applicable law, statute or
rule which narrows the right of a Delaware corporation to indemnify such
changes, to the extent not otherwise required by such law, statute or rule to
be applied to this Agreement shall have no effect on this Agreement or the
parties’ rights and obligations hereunder. The indemnification provided by this
Agreement shall not be deemed exclusive of any rights to which the Executive
may be entitled under the Company’s Certificate of Incorporation, the Bylaws,
any agreement, any vote of stockholders or disinterested directors, the
Delaware General Corporation Law, or otherwise. The indemnification provided
under this Agreement shall continue to remain valid and enforceable by the
Executive even though the Executive may have ceased to be an officer,
supervisor, director, or employee of the Company or Executive’s employment with
the Company under this Agreement has ceased.

5. TERMINATION

          5.1
Termination
With Good Cause; Resignation Without Good Reason. Company may
terminate Executive’s employment at any time, with or without notice or Good
Cause (as defined below). If Company terminates Executive’s employment with
Good Cause, or if Executive resigns without Good Reason (as defined below),
Company will pay Executive his salary prorated through the date of termination,
at the rate in effect at the time notice of termination is given, together with
any benefits accrued through the date of termination. Company will have no
further obligations to Executive under this Agreement or any other agreement,
and all unvested options will terminate.

          5.2
Termination
Without Good Cause; Resignation with Good Reason. Company will have
the right to terminate Executive’s employment under this Agreement without Good
Cause at any time, and Executive will have the right to terminate his
employment with notice and Good Reason at any time. If Company terminates
Executive’s employment without Good Cause, or Executive resigns for Good
Reason, the Company will pay Executive his salary through the end of the Term
of this Agreement.

          5.3
Good
Cause. For purposes of this Agreement, a termination will be for
“Good Cause” if Executive should:

                    (a)
commit an act of fraud, moral turpitude or embezzlement in connection

-4-

with his
duties;

                    (b)
violate a material provision of Company’s written Codes of Ethics as adopted by
the Board, or any applicable state or federal law or regulation which failure
or refusal remains uncured for a period of fifteen (15) days after written
notice to Executive thereof;

                    (c)
violate or breach a material provision of the this Agreement (other than a
breach by reason of an act described in subclauses (a) above or (e) below),
which breach remains uncured for a period of fifteen (15) days after written
notice to Executive of the breach;

                    (d)
fail or refuse to comply with a relevant and material obligation assumable and
chargeable to an executive of his corporate rank and responsibilities under the
Sarbanes-Oxley Act and the regulations of the Securities and Exchange
Commission promulgated thereunder which failure or refusal remains uncured for
a period of fifteen (15) days after written notice to Executive thereof; or

                    (e)
be convicted of, or enter a plea of guilty or no contest to, a felony or a
misdemeanor involving fraud or moral turpitude under state or federal law.

          5.4
Good
Reason. For purposes of this Agreement, a resignation will be with
“Good Reason” following:

                    (a)
assignment to Executive of duties materially inconsistent with Executive’s
status as President of an emerging company; provided Executive will give the
Company written notice and a reasonable opportunity to cure prior to
termination for this reason, 

                    (b)
removal of Executive as President, 

                    (c)
material adverse change in the reporting relationship set forth in Section 2.1
hereof or a substantial reduction in the nature or status of Executive’s
responsibilities as President provided Executive will give the Company written
notice and a reasonable opportunity to cure prior to termination for this
reason; or

                    (d)
material breach of this Agreement by Company, including, but not limited to,
Company’s failure to timely pay to Executive any amount due under Section 3.2
hereof which continues after written notice and reasonable opportunity to cure.

Notwithstanding
the above, the occurrence of an event specified in Sections 5.4(a), (b) or (c)
above shall not give rise to a right of termination by Executive for Good
Reason if any of such events is the result of an action taken by the Company by
reason of the fact that the Company had the right to terminate the Executive
for Good Cause as defined in Section 5.3, but, rather than terminate Executive,
the Company has chosen to retain Executive and reassign Executive to different
duties as a result of the conduct of Executive. 

-5-

          5.5
Death or
Disability. To the extent consistent with applicable law,
Executive’s salary will terminate on his death or Disability. “Disability”
means any health condition, physical or mental, or other cause beyond
Executive’s control that prevents him from performing his duties, even after
reasonable accommodation is made by Company, for a period of 90 consecutive days
within any 365-day period. In the event of termination due to death or
Disability, Company will pay Executive (or his legal representative) his salary
prorated through the date of termination, at the rate in effect at the time of
termination and continue to provide insurance and other fringe benefits to
Executive and Executive’s spouse and dependent children for a period of one
year from Executive’s termination date, and 100% of the options set to vest in
the year that death or disability occurs will vest and Executive (or his legal
representative) will have until the end of the option term to exercise all
options. Company will have no further obligations to Executive (or his legal
representative) under this Agreement, except for any other vested rights under
employee benefit plans and programs and the right to receive reimbursement for
business expenses.

          5.6
Return of
Company Property. Within ten days after the effective date of
termination of Executive’s employment with Company, Executive will return to
Company all products, books, records, forms, specifications, formulae, data
processes, designs, papers and writings relating to the business of Company,
including, but not limited to, proprietary or licensed computer programs,
customer lists and customer data, and copies or duplicates thereof in
Executive’s possession or under Executive’s control. Executive will not retain
any copies or duplicates of such property and all licenses granted to him by
Company to use computer programs or software will be revoked on the termination
date.

6. DUTY OF LOYALTY

During the
term of this Agreement the executive will follow the Vycor Code of Ethics.

7. CONFIDENTIAL INFORMATION

          7.1
Trade
Secrets of Company. Executive, by reason of his prior employment with
the Company and during the term of this Agreement, has and will develop, have
access to and become acquainted with various trade secrets which are owned by
Company and which are regularly used in the operation of its business.
Executive will not disclose such trade secrets, directly or indirectly, or use
them in any way, either during the term of this Agreement or at any time
thereafter, except as required in the course of his employment by Company. All
files, contracts, manuals, reports, letters, forms, documents, notes,
notebooks, lists, records, documents, customer lists, vendor lists, purchase
information, designs, computer programs and similar items and information
relating to the businesses of such entities, whether prepared by Executive or
otherwise and whether now existing or prepared at a future time, coming into
his possession will remain the exclusive property of Company.

          7.2
Confidential
Data of Customers of Company. Executive, in the course of his
duties, will have access to and become acquainted with financial, accounting,
statistical and personal data of customers of Company and of its and their
affiliates. All such data is confidential and will not be disclosed, directly
or indirectly, or used by Executive in any way, either during the term of this 

-6-

Agreement
(except as required in the course of Executive’s employment by Company) or at
any time thereafter.

          7.3
Intellectual
Properties. Executive will sign a Confidentiality Agreement (the
“Confidentiality Agreement”) with the Company prior to or on his start date.

          7.4
Continuing
Effect. The provisions of this Section 7 will remain in effect after
the effective date of termination of Executive’s employment with Company

8. OTHER PROVISIONS

          8.1
Compliance
with Other Agreements. Executive represents and warrants to Company
that, to his knowledge and belief, the execution, delivery and performance of
this Agreement will not conflict with or result in the violation or breach of
any term or provision of any order, judgment, injunction, contract, agreement,
commitment or other arrangement to which Executive is a party or by which he is
bound.

          8.2
Non-delegable
Duties. This Agreement is a contract for Executive’s personal
services. The duties of Executive under this Agreement are personal and may not
be delegated or transferred in any manner whatsoever, and will not be subject
to involuntary alienation, assignment or transfer by Executive during his life.

          8.3
Governing
Law. The validity, construction and performance of this Agreement
will be governed by the internal laws of the State of New York. The federal and
state courts located in New York, New York will have exclusive jurisdiction
over any action to compel performance in accordance with this Agreement, the
Confidentiality Agreement or the Dispute Resolution Agreement (as defined
below) or to enforce any award in any arbitration

          8.4
Severability.
The invalidity or unenforceability of any particular provision of this
Agreement will not affect the other provisions, and this Agreement will be
construed in all respects as if any invalid or unenforceable provision were
omitted.

          8.5
Binding
Effect. The provisions of this Agreement will bind and inure to the
benefit of the parties hereto and their respective successors and permitted
assigns.

          8.6
Notice.
Any notices or communications required or permitted by this Agreement will be
deemed sufficiently given if in writing and when delivered personally or two
business days after deposit with the United States Postal Service as registered
or certified mail, postage prepaid and addressed as follows:

                    (a)
if to Company, to the principal office of Company in the State of New York,
marked “Attention: Chairman of the Board”, and to a member of the Company’s
Compensation Committee who also qualifies as an “independent” member of the
board of directors; or

-7-

                    (b)
if to Executive, to the most recent address for Executive appearing in Company’s
records.

          8.7
Dispute
Resolution. The parties agree to submit any disputes arising from
this Employment Agreement to final and binding arbitration under the applicable
Rules of the American Arbitration Association.

          8.8
Attorneys’
Fees. The prevailing party in any suit or other proceeding brought
to enforce, interpret or apply any provisions of this Agreement will, except as
otherwise provided in the Dispute Resolution Agreement, be entitled to recover
all costs and expenses of the proceeding and investigation (not limited to
court costs), including attorneys’ fees.

          8.9
Headings.
The headings contained in this Agreement are for reference purposes only and
will not affect in any way the meaning or interpretation of this Agreement.

          8.10
Amendment
and Waiver. This Agreement may be amended, modified or supplemented
only by a writing executed by each of the parties hereto, and by Fountainhead,
so long as Fountainhead retains an ownership position in the Company. Either
party may in writing waive any provision of this Agreement to the extent such
provision is only for the benefit of the waiving party, and no other party,
including Fountainhead, who shall be deemed a third party beneficiary for the
purposes set forth herein. No waiver by either party of a breach of any
provision of this Agreement will be construed as a waiver of any subsequent or
different breach, and no forbearance by a party to seek a remedy for
noncompliance or breach by the other party will be construed as a waiver of any
right or remedy with respect to such noncompliance or breach.

          8.11
Entire
Agreement. This Agreement and all other written agreements entered
into with Executive during his employment with Company, are the only agreements
and understandings between the parties hereto pertaining to the subject matter
hereof, and supersede all prior agreements, summaries of agreements,
descriptions of compensation packages, discussions, negotiations,
understandings, representations or warranties, whether verbal or written,
between the parties pertaining to such subject matter.

          8.12
Authority.
Company represents and warrants that the individual executing this Agreement on
its behalf has been duly authorized so to do and that this Agreement is a valid
and enforceable agreement of Company.

          IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date
first above written.

-8-

VYCOR MEDICAL, INC.

	
  

 	
  

 	
  

 
	
  

 	
 /s/ Heather Vinas

 	
  

 
	
 By:

 	
  

 	
  

 
	
  

 	 

 	
  

 
	
 Name:
 Heather Vinas

 	
  

 
	
 Title: President

 	
  

 
	
  

 	
 /s/ Kenneth T. Coviello

 	
  

 
	
  

 	 

 	
  

 
	
  

 	
 Kenneth T. Coviello

 	
  

 

-9-

Exhibit A

Position
and Duties.

The Executive
shall serve as President of the Company; the Executive’s duties will be the
following: 

          (a) Manage
the business and affairs of the Company within the guidelines established by
the Board of Directors with primary responsibility for business development and
sales; 

          (b) Work with the President to
recommend
to the Board of Directors strategic directions for the Company’s business, and
when approved by the Board of Directors, implement the corresponding strategic,
business and operational plans;

          (c) Direct and monitor the
activities of
the Company in a manner such that agreed upon targets are met and the assets of
the Company are safeguarded and optimized in the best interests of all the
Company’s shareholders;

          (d) Together with the President,
develop
and implement operational policies to guide the Company within the parameters
set forth in the Company’s By-Laws and the framework of the strategic
directions adopted by the Board of Directors;

          (e) Develop and recommend top-level
organizational structure and staffing to the Board of Directors and direct the
implementation of the Board’s decisions in this regard;

          (f) Together with the President,
develop
and seek the Board’s concurrence for plans for management development and
succession in all key positions and then implement such plans;

          (g)
Manage and oversee the interface between the Company and its shareholders, the
investment community, media, governments and their agencies, employees and the
general public;

          (h) Meet regularly and as required
with
the Chairman and other members of the Board of Directors to ensure that they are
provided in a timely manner with all information and access to management
necessary to permit the Board of Directors and all Committees thereof to
fulfill their statutory and other obligations;

-10-

          i) Together with the President,
develop and
recommend to the Board of Directors the Annual Budget and Plan and
provide to the Board of Directors, on at least an annual basis, a management
proposal that outlines the Company’s budget and plan of operations;

          (j) Such other duties and
responsibilities
consistent with such office, as from time to time may be prescribed by the
Board of Directors of the Company (or Committees thereof)

-11-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]